Format
Sort by

Send to:

Choose Destination

Results: 2

1.

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.

Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrútia G, Valentini M, Wang Y, Peto R; Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group.

Lancet. 2013 Mar 9;381(9869):805-16. Erratum in: Lancet. 2013 Mar 9;381(9869):804.

PMID:
23219286
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

[Anesthetic considerations in the cancer patient].

Unzueta Merino MC, Piera Pibernat JM, Aliaga Font L, Moral García MV, Castro Fernández MA, Villar Landeira JM.

Rev Esp Anestesiol Reanim. 1986 Nov-Dec;33(6):435-9. Spanish. No abstract available.

PMID:
3823534
[PubMed - indexed for MEDLINE]

Supplemental Content

Loading ...
Write to the Help Desk